Initiator Pharma (Sweden) Performance
| INIT Stock | 3.00 0.13 4.53% |
Initiator Pharma has a performance score of 2 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 0.46, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Initiator Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Initiator Pharma is expected to be smaller as well. Initiator Pharma right now retains a risk of 2.76%. Please check out Initiator Pharma coefficient of variation, jensen alpha, sortino ratio, as well as the relationship between the information ratio and total risk alpha , to decide if Initiator Pharma will be following its current trending patterns.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Initiator Pharma AS are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively stable basic indicators, Initiator Pharma is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Initiator |
Initiator Pharma Relative Risk vs. Return Landscape
If you would invest 290.00 in Initiator Pharma AS on November 12, 2025 and sell it today you would earn a total of 10.00 from holding Initiator Pharma AS or generate 3.45% return on investment over 90 days. Initiator Pharma AS is generating 0.0954% of daily returns and assumes 2.755% volatility on return distribution over the 90 days horizon. Simply put, 24% of stocks are less volatile than Initiator, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Initiator Pharma Target Price Odds to finish over Current Price
The tendency of Initiator Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 3.00 | 90 days | 3.00 | about 34.05 |
Based on a normal probability distribution, the odds of Initiator Pharma to move above the current price in 90 days from now is about 34.05 (This Initiator Pharma AS probability density function shows the probability of Initiator Stock to fall within a particular range of prices over 90 days) .
Initiator Pharma Price Density |
| Price |
Predictive Modules for Initiator Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Initiator Pharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Initiator Pharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Initiator Pharma is not an exception. The market had few large corrections towards the Initiator Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Initiator Pharma AS, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Initiator Pharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.03 | |
β | Beta against Dow Jones | 0.46 | |
σ | Overall volatility | 0.1 | |
Ir | Information ratio | -0.007 |
Initiator Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Initiator Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Initiator Pharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Net Loss for the year was (21.06 M) with loss before overhead, payroll, taxes, and interest of (21.63 M). | |
| Initiator Pharma generates negative cash flow from operations |
Initiator Pharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Initiator Stock often depends not only on the future outlook of the current and potential Initiator Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Initiator Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 47.9 M | |
| Cash And Short Term Investments | 34.1 M |
Initiator Pharma Fundamentals Growth
Initiator Stock prices reflect investors' perceptions of the future prospects and financial health of Initiator Pharma, and Initiator Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Initiator Stock performance.
| Return On Equity | -1.05 | |||
| Return On Asset | -0.49 | |||
| Current Valuation | 256.25 M | |||
| Shares Outstanding | 52.36 M | |||
| Price To Book | 5.64 X | |||
| EBITDA | (23.06 M) | |||
| Total Debt | 13.29 M | |||
| Book Value Per Share | 0.71 X | |||
| Cash Flow From Operations | (34.1 M) | |||
| Earnings Per Share | (0.79) X | |||
| Total Asset | 53.7 M | |||
About Initiator Pharma Performance
Assessing Initiator Pharma's fundamental ratios provides investors with valuable insights into Initiator Pharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Initiator Pharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about Initiator Pharma performance evaluation
Checking the ongoing alerts about Initiator Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Initiator Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Net Loss for the year was (21.06 M) with loss before overhead, payroll, taxes, and interest of (21.63 M). | |
| Initiator Pharma generates negative cash flow from operations |
- Analyzing Initiator Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Initiator Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Initiator Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Initiator Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Initiator Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Initiator Pharma's stock. These opinions can provide insight into Initiator Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Initiator Stock Analysis
When running Initiator Pharma's price analysis, check to measure Initiator Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Initiator Pharma is operating at the current time. Most of Initiator Pharma's value examination focuses on studying past and present price action to predict the probability of Initiator Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Initiator Pharma's price. Additionally, you may evaluate how the addition of Initiator Pharma to your portfolios can decrease your overall portfolio volatility.